Guggenheim analyst Michael Schmidt raised the firm’s price target on Exelixis (EXEL) to $45 from $42 and keeps a Buy rating on the shares, citing increased FY25 revenue guidance and the firm’s revised estimates for Cabometyx following “an impressive net product revenues beat” in Q1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $56 from $45 at Citi
- Exelixis: Hold Rating Amid Strong Revenue and Uncertain Prospects
- Exelixis price target raised to $44 from $38 at TD Cowen
- Exelixis: Strong Financial Performance and Growth Potential Justify Buy Rating
- Exelixis price target raised to $47 from $40 at Morgan Stanley